{"transactions":[{"id":691009,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":165519,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Fund II, L.P. (\"Fund II\"). The general partner of Fund II is Westlake BioPartners GP II, LLC (\"GP II\"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":165519},"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":691008,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":2066857,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Opportunity Fund\"). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC (\"Opportunity GP\"). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. Seidenberg is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2066857},"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":691007,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1484401,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Fund II, L.P. (\"Fund II\"). The general partner of Fund II is Westlake BioPartners GP II, LLC (\"GP II\"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1484401},"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":691006,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":3464072,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Fund II, L.P. (\"Fund II\"). The general partner of Fund II is Westlake BioPartners GP II, LLC (\"GP II\"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3464072},"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":691005,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1027635,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Fund I\"). The general partner of Fund I is Westlake BioPartners GP I, LLC (\"GP I\"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg (\"Seidenberg\") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1027635},"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":691004,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":3547842,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Fund I\"). The general partner of Fund I is Westlake BioPartners GP I, LLC (\"GP I\"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg (\"Seidenberg\") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3547842},"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":691003,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Convertible Preferred Stock","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":938979,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Fund I\"). The general partner of Fund I is Westlake BioPartners GP I, LLC (\"GP I\"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg (\"Seidenberg\") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":938979},"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":691002,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":2066857,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Opportunity Fund\"). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC (\"Opportunity GP\"). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. Seidenberg is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":2094813,"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":691001,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":165519,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Fund II, L.P. (\"Fund II\"). The general partner of Fund II is Westlake BioPartners GP II, LLC (\"GP II\"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":5160847,"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":691000,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1484401,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Fund II, L.P. (\"Fund II\"). The general partner of Fund II is Westlake BioPartners GP II, LLC (\"GP II\"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":4995328,"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":690999,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":3464072,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Fund II, L.P. (\"Fund II\"). The general partner of Fund II is Westlake BioPartners GP II, LLC (\"GP II\"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":3510927,"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":690998,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1027635,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Fund I\"). The general partner of Fund I is Westlake BioPartners GP I, LLC (\"GP I\"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg (\"Seidenberg\") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":5944009,"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":690997,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":3547842,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Fund I\"). The general partner of Fund I is Westlake BioPartners GP I, LLC (\"GP I\"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg (\"Seidenberg\") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":4916374,"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":690996,"issuer":{"id":4709,"kind":"organization","name":"Latigo Biotherapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24701,"kind":"organization","name":"Westlake BioPartners Fund II, L.P.","position":3,"cik":"0001811947","reported_name":"Westlake BioPartners Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24702,"kind":"organization","name":"Westlake BioPartners GP II, LLC","position":4,"cik":"0001811948","reported_name":"Westlake BioPartners GP II, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":5,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":6,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T10:00:58.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":938979,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Fund I\"). The general partner of Fund I is Westlake BioPartners GP I, LLC (\"GP I\"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg (\"Seidenberg\") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose."}],"balance_after":1368532,"source":{"system":"sec-edgar","filing":"0001104659-26-093633","document":"tm2622668-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2056611/000110465926093633/tm2622668-1_4seq1.xml","form_type":"4"}},{"id":961035,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":1,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":2,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":3,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":4,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-22T16:42:37.000Z","date":"2025-12-18","kind":"purchase","planned":false,"acquired":true,"shares":133333,"price":7.5,"value":999997.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Westlake Opportunity\"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC (\"Westlake Opportunity GP I\"). The voting and dispositive control over Westlake Opportunity GP I is held by the managing director of Westlake Opportunity GP I, Beth Seidenberg, and whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any. Sean Harper, a Reporting Person on Westlake Opportunity's prior Section 16 filings with respect to the Issuer, is no longer a managing director of Westlake Opportunity GP I, and accordingly, is not a Reporting Person on this Form 4."}],"balance_after":869317,"source":{"system":"sec-edgar","filing":"0001104659-25-123596","document":"tm2534053-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465925123596/tm2534053-1_4seq1.xml","form_type":"4"}},{"id":1643272,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":3,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":4,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12102,"kind":"person","name":"Harper Sean E","position":5,"cik":"0001541946","reported_name":"Harper Sean E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2024-02-14T22:35:32.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":3349538,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Westlake Opportunity\"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC (\"Westlake Opportunity GP I\"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":735984},"source":{"system":"sec-edgar","filing":"0001104659-24-024091","document":"tm246188-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465924024091/tm246188-1_4seq1.xml","form_type":"4"}},{"id":1643271,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":3,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":4,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12102,"kind":"person","name":"Harper Sean E","position":5,"cik":"0001541946","reported_name":"Harper Sean E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2024-02-14T22:35:32.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":4006624,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":880364},"source":{"system":"sec-edgar","filing":"0001104659-24-024091","document":"tm246188-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465924024091/tm246188-1_4seq1.xml","form_type":"4"}},{"id":1643270,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":3,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":4,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12102,"kind":"person","name":"Harper Sean E","position":5,"cik":"0001541946","reported_name":"Harper Sean E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Redeemable Convertible Preferred Stock","published_at":"2024-02-14T22:35:32.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":8830901,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1940388},"source":{"system":"sec-edgar","filing":"0001104659-24-024091","document":"tm246188-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465924024091/tm246188-1_4seq1.xml","form_type":"4"}},{"id":1643269,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":3,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":4,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12102,"kind":"person","name":"Harper Sean E","position":5,"cik":"0001541946","reported_name":"Harper Sean E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Redeemable Convertible Preferred Stock","published_at":"2024-02-14T22:35:32.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":4401771,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":967188},"source":{"system":"sec-edgar","filing":"0001104659-24-024091","document":"tm246188-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465924024091/tm246188-1_4seq1.xml","form_type":"4"}},{"id":1643268,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":3,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":4,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12102,"kind":"person","name":"Harper Sean E","position":5,"cik":"0001541946","reported_name":"Harper Sean E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T22:35:32.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":735984,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Westlake Opportunity\"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC (\"Westlake Opportunity GP I\"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":735984,"source":{"system":"sec-edgar","filing":"0001104659-24-024091","document":"tm246188-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465924024091/tm246188-1_4seq1.xml","form_type":"4"}},{"id":1643267,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":3,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":4,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12102,"kind":"person","name":"Harper Sean E","position":5,"cik":"0001541946","reported_name":"Harper Sean E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T22:35:32.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":3787940,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":3787940,"source":{"system":"sec-edgar","filing":"0001104659-24-024091","document":"tm246188-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465924024091/tm246188-1_4seq1.xml","form_type":"4"}}]}